Intraocular lymphoma

Summary

Intraocular lymphoma (MONDO:0004351) is a cancer and 67 clinical trials. Top therapeutic interventions include fludarabine phosphate, foscarnet, and bendamustine hydrochloride. A subtype of eye lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: Unknown (Worldwide)
• Clinical trials: 67

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intraocular lymphoma
Mondo ID	MONDO:0004351
MeSH	D064090
Orphanet	279904
DOID	DOID:775
NCIT	C9184
SNOMED CT	420788006
UMLS	C0281658
MedGen	79344
GARD	0021063
Is cancer (heuristic)	yes

Also known as: intraocular lymphoma · PIOL · primary intraocular lymphoma · primary intraocular non-Hodgkin’s lymphoma

Disease family

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › eye lymphoma › intraocular lymphoma

Related subtypes (4): retina lymphoma, primary oculocerebral lymphoma, primary lymphoma of the conjunctiva, primary vitreoretinal large b-cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 67.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	33
PHASE2	18
Not specified	9
PHASE1/PHASE2	6
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06973811	PHASE2	NOT_YET_RECRUITING	ZR-MTX for PIOL Phase II Trial
NCT00006251	PHASE1/PHASE2	COMPLETED	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
NCT00049504	PHASE2	COMPLETED	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
NCT00054639	PHASE2	COMPLETED	Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
NCT00072514	PHASE2	COMPLETED	Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
NCT00089011	PHASE2	COMPLETED	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
NCT00089076	PHASE1/PHASE2	TERMINATED	MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
NCT00118352	PHASE2	COMPLETED	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
NCT00867529	PHASE2	COMPLETED	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
NCT01110135	PHASE2	COMPLETED	Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
NCT01177371	PHASE2	COMPLETED	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
NCT01258998	PHASE2	COMPLETED	Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
NCT01273766	PHASE2	COMPLETED	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
NCT01326702	PHASE1/PHASE2	COMPLETED	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
NCT01419795	PHASE2	TERMINATED	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
NCT01427881	PHASE2	COMPLETED	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
NCT01652014	PHASE2	WITHDRAWN	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
NCT01789255	PHASE2	COMPLETED	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
NCT01805037	PHASE1/PHASE2	TERMINATED	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
NCT01839916	PHASE2	COMPLETED	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02213913	PHASE1/PHASE2	COMPLETED	Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
NCT02281279	PHASE1/PHASE2	WITHDRAWN	Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
NCT02542514	PHASE2	COMPLETED	Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma
NCT03746223	PHASE2	UNKNOWN	Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma
NCT01815749	PHASE1	ACTIVE_NOT_RECRUITING	Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
NCT00003970	PHASE1	COMPLETED	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
NCT00004241	PHASE1	COMPLETED	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
NCT00025415	PHASE1	COMPLETED	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
NCT00077155	PHASE1	COMPLETED	Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00089271	PHASE1	COMPLETED	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
NCT00098891	PHASE1	COMPLETED	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
NCT00101205	PHASE1	TERMINATED	Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
NCT00221325	PHASE1	COMPLETED	A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma
NCT00293345	PHASE1	COMPLETED	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00348985	PHASE1	COMPLETED	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00354185	PHASE1	TERMINATED	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
NCT00458731	PHASE1	COMPLETED	Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
NCT00499811	PHASE1	COMPLETED	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
NCT00608361	PHASE1	COMPLETED	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
NCT00720135	PHASE1	COMPLETED	Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUDARABINE PHOSPHATE	4	9
FOSCARNET	4	4
BENDAMUSTINE HYDROCHLORIDE	4	3
DEXRAZOXANE	4	3
BELINOSTAT	4	2
ALEMTUZUMAB	4	1
BRENTUXIMAB VEDOTIN	4	1
DEFERASIROX	4	1
GANCICLOVIR	4	1
IPILIMUMAB	4	1
ISOTRETINOIN	4	1
ROMIDEPSIN	4	1
VALGANCICLOVIR	4	1
TANESPIMYCIN	3	2
VELIPARIB	3	2
6-O-BENZYLGUANINE	3	1
ALISERTIB	3	1
CEDIRANIB MALEATE	3	1
CILENGITIDE	3	1
CPI 613	3	1
ENTINOSTAT	3	1
OBATOCLAX MESYLATE	3	1
OBLIMERSEN SODIUM	3	1
TRIAPINE	3	1
METHOXYAMINE	2	2
AR-42	2	1
ALVESPIMYCIN HYDROCHLORIDE	1	1
DI-LEU16-IL2	1	1
CHEMBL4786163	0	2
CHEMBL4066465	0	1